---
search:
  boost: 2 
---

# Lipotropics

This is a subcategory of Cardiovascular Agents.

## Formulary

### Preferred

| Preferred                    | Generic Name | Quantity | Time (Days) |
| :--------------------------- | :----------- | :------: | :---------: |
| Atorvastatin <sup>QL</sup>           | Atorvastatin Calcium Tab (all strengths           | 102         | 102            |
| Cholestyramine Regular, Light        |              |          |             |
| Colestipol Tab               |              |          |             |
| Ezetimibe                    |              |          |             |
| Fenofibrate 48 and 145mg Tab <sup>QL</sup> | Fenofibrate Tab 48 MG & 145 MG            | 102         |   102          |
| Gemfibrozil <sup>QL</sup>                  |  Gemfibrozil Tab            |   204       |   102          |
| Lovastatin <sup>QL</sup>                  |  Lovastatin Tab (all strengths)      |   204       |    102         |
| Omega-3-Acid Ethyl Esters    |              |          |             |
| Niacin IR, ER OTC <sup>QL</sup>                   | Niacin ER Tab (all strengths excl 500 MG)             | 204         |         102    |
| Niacin IR, ER OTC <sup>QL</sup>                   | Niacin ER Tab 500 MG             |   306       |  102           |
| Praluent <sup>PA</sup>                 |              |          |             |
| Pravastatin                  | Pravastatin Sodium (all strengths)           | 102         |  102           |
| Prevalite                    |              |          |             |
| Repatha <sup>PA</sup>                   |              |          |             |
| Rosuvastatin <sup>QL</sup>                |  Rosuvastatin Calcium Tab (all strengths)            | 102         |             102 |
| Simvastatin <sup>QL</sup>                | Simvastatin Tab (all strengths)       | 102         |  102           |

### Non-Preferred

| Non-Preferred                                          | Generic Name | Quantity | Time (Days) |
| :----------------------------------------------------- | :----------- | :------: | :---------: |
| Altoprev                                               |              |          |             |
| Amlodipine / Atorvastatin                                |              |          |             |
| Colesevelam                                            |              |          |             |
| Colestipol Granules                                    |              |          |             |
| Ezetimibe / Simvastatin                                  |              |          |             |
| Ezallor                                                |              |          |             |
| Fenofibrate Cap <sup>QL</sup>                                      |  Fenofibrate Cap (all strengths)            | Determined pursuant to PA         |  Determined pursuant to PA           |
| Fenofibrate 40, 54, 120 and 160mg Tab <sup>QL</sup>                 |    Fenofibrate Tab (all strengths excl 48 MG & 145 MG)          |      Determined pursuant to PA    |     Determined pursuant to PA        |
| Fenofibric Acid <sup>QL</sup>                                       | Fenofibric Acid Tab (all strengths)             |        Determined pursuant to PA |  Determined pursuant to PA           |
| Fenofibric Acid DR <sup>QL</sup>                                       |   Choline Fenofibrate DR Cap (all strengths)           | 102         |  102           |
| Fluvastatin                                            |              |          |             |
| Juxtapid                                                |             |          |             |
| Livalo                                                 |              |          |             |
| Nexletol                                               |              |          |             |
| Nexlizet                                               |              |          |             |
| Niacin ER Tab <sup>QL</sup>                                          | Niacin ER Tab (all strengths excl 200 MG)            |      204    | 102            |
| Niacin ER Tab <sup>QL</sup>                                          | Niacin ER Tab 500 MG          |  408        |             102 |
| Vascepa                                                |              |          |             |
| Zypitamag                                              |              |          |             |

## Length of Authorizations

See below

|        |                               |
| --------------------------- | ------------------------------------------------- |
| Juxtapid (Initial)  | 180 days |
| Vascepa, Lovaza, ACL inhibitors (Initial) | 84 days |
| All others (Initial and Subsequent) | 365 days |

## All Authorizations 

Must be prescribed in accordance with FDA approved labeling

## Clinical PA Criteria

- Must provide documentation of baseline labs **AND** have documented adherence to **90 days** of prescribed lipid lowering medications
- Must have had an inadequate clinical response of at least **90 days AND** unable to reach goal LDL-C (see below) despite treatment with maximally tolerated dose of highpotency statin and ezetimibe (or a clinical reason that these drugs cannot be utilized)

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **14 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Additional Criteria

### Lovastatin ER (Altoprev), Pitavastatin (Livalo), Fluvastatin (Lescol)

Additional Lovastatin ER (Altoprev), Pitavastatin (Livalo), Fluvastatin (Lescol) Criteria

- Must have had an inadequate clinical response of at least **30 days** with **two preferred** drugs in the same drug class

### Colesevelam (Welchol)

Additional Criteria for Colesevelam (Welchol)

- Must provide documentation of a Type 2 Diabetes diagnosis

### Icosapent Ethyl (Vascepa)

Additional Icosapent Ethyl (Vascepa) Criteria

- Must provide documentation of baseline labs indicating triglyceride levels ≥500mg/dL after an inadequate clinical response to fibrates, niacin, and diet/exercise
- Must provide documentation of discontinuation of drugs known to increase triglyceride levels (i.e., beta blockers, thiazides, and estrogens), if clinically appropriate

### Lomitapide (Juxtapid) & ATP Citrate Lysase (ACL) Inhibitor

Additional Lomitapide (Juxtapid) & ATP Citrate Lysase (ACL) Inhibitor Criteria

- Must provide documentation of baseline labs **AND** have documented adherence to **90 days** of prescribed lipid lowering medications
- Must have had inadequate clinical response of at least **90 days AND** unable to reach goal LDL-C with high-potency statin, ezetimibe and PCSK9 inhibitor (or a clinical reason that these drugs cannot be utilized)

## Additional Information

- High potency statins: atorvastatin (Lipitor) 40-80mg & rosuvastatin (Crestor) 20-40mg
- LDL goals for **Familial Hypercholesterolemia** (includes Heterozygous & Homozygous FH): LDL ≤ 100mg/dL for adults or LDL ≤ 110mg/dL for those < 18 years of age
- LDL goals for **Clinical Atherosclerotic Cardiovascular Disease (ASCVD)**: LDL ≤ 70mg/dL

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=22)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=12)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
